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Antimicrobial peptides (AMPs) are activated in response to septic injury and have important roles in vertebrate and invertebrate
immune systems. AMPs act directly against pathogens and have both wound healing and antitumor activities. Although
coleopterans comprise the largest and most diverse order of eukaryotes and occupy an earlier branch than Drosophila in the
holometabolouslineageofinsects,theirimmunesystemhasnotbeenstudiedextensively.Initialresearchreports,however,indicate
that coleopterans possess unique immune response mechanisms, and studies of these novel mechanisms may help to further
elucidate innate immunity. Recently, the complete genome sequence of Tribolium was published, boosting research on coleopteran
immunity and leading to the identiﬁcation of Tribolium AMPs that are shared by Drosophila a n dm a m m a l s ,a sw e l la so t h e r
AMPs that are unique. AMPs have potential applicability in the development of vaccines. Here, we review coleopteran AMPs, their
potential impact on clinical medicine, and the molecular basis of immune defense.
1. Overview
Research on innate immunity has led to an accumulation of
information that oﬀers prospects for the development of an-
timicrobial therapeutic drugs and vaccines. The low rate of
discovery of new antibiotics, the emergence of multiple-drug
resistance, and the alarming death rate due to infection indi-
cate a clear need for the development of alternative means to
combat infections. A highlight of the 20th century was the
discovery of vaccines that led to the eradication of diseases
such as polio, small pox, and others. Even after more than
two decades, however, a vaccine against the highly mutable
human immune-deﬁciency virus remains to be developed,
illustrating the need for new strategies to produce vaccines.
A better understanding of innate immunity has revealed im-
portant links between innate and adaptive immune systems
that could lead to eﬀective approaches in vaccine develop-
ment.
Coleopterans comprise 40% of the 360,000 currently
known insect species and are therefore the largest and most
diverse order of eukaryotic organisms [1]. Tribolium, the co-
leopteran model, is proposed to be a better model than
Drosophila, especially for evolutionary studies, as it is ac-
knowledged to be the most evolutionarily successful meta-
zoan and to be more representative of insects in general than
Drosophila [1, 2]. Coleopterans, with no adaptive immunity,
thrive on this planet. Studies of the molecular basis of cole-
opteran immunity could therefore lead to a better under-
standing of the evolution of the innate immune system.
Much of the work on innate immunity and studies of the
functional aspects of antimicrobial peptides (AMPs) has
been performed using Drosophila, which represents dipter-
ans, while studies on coleopterans lag behind. Insects and
humans share innate immunity, but humans also have adap-
tive immunity. Some of the conserved molecular signaling
pathways that are used by insects and humans for immune
defense are also used for early embryonic development in
insects, but there are notable diﬀerences, probably due to
the fact that the innate immune systems of invertebrates and
vertebrates diverged some 800 million years ago, and adap-
tive immunity appeared in the vertebrate branch only about
500 million years ago [3, 4]. The divergence of dipterans
and coleoptera occurred some 284 million years ago, and
Drosophila, in the dipteran branch, exhibits a remarkably2 International Journal of Microbiology
accelerated protein evolution [5]. Furthermore, despite these
separate evolutionary paths, molecular coevolution could
have occurred between coleoptera and mammals due to in-
terdependence, that is, sharing common habitats and resour-
ces.
While the majority of the work on immunity has been
conducted using Drosophila as a model, there is evidence
that coleoptera has retained many ancestral vertebrate genes,
suggesting that studies of coleoptera could provide more
insightintothepropertiesandevolutionofinnateimmunity.
For example, Tribolium has many ancestral genes that are
present in vertebrates and absent in Drosophila [6]. Similarly,
the sequenced Tribolium genome revealed that ancestral
genes involved in cell-cell communication and development
are retained in Tribolium, but not in Drosophila [2]. Further-
more, in homology searches, human genes compare signiﬁ-
cantly better with Tribolium than Drosophila [5].
AMPs are small peptides characterized by an overall pos-
itive charge (cationic), hydrophobicity, and amphipathicity.
Structurally, they fall into two broad groups: linear α-helical
and cysteine-containing forms with one or more disulﬁde
bridges and β-hairpin-like, β-sheet, or mixed α-helical/β-
sheet structures. The peptides assume these conformations
upon contact with the target membranes [7–9]. Their char-
acteristic physicochemical properties facilitate interactions
with the phospholipid bilayer in the cell membranes of
pathogens [10–12]. AMPs have been shown to kill pathogens
directly by disrupting their membranes using mechanisms
that are not fully understood. Several models, however,
have been proposed. First, there is the “barrel-stave” model
whereby a transmembrane pore is created by amphipathic α-
helicalpeptides,disrupting thecellmembraneofapathogen.
Second, the “carpet” model proposes that the peptides
solubilize the membrane by interacting with the lipid head
groups on the pathogen cell surface. This model was also
proposed for viral killing [13]. Another is the aggregation
model that is exhibited by sapecin from Sarcophaga pereg-
rina, based on the existence of hydrophobic and hydrophilic
domains on the AMPs. These structural features allow
the peptides to form pores with hydrophilic walls and
hydrophobic regions facing the acyl side chains of pathogen
membrane phospholipids, thus facilitating movement of
hydrophilic molecules through the pore [14]. Finally, the
toroidal model, a subtle variation of the aggregation model,
involves the formation of a dynamic lipid-layer core by
hydrophilic regions of the peptide and lipid head groups
and is induced by magainins, melittin, and protegrins [15–
17]. While the indispensability of the structural features
of cationic peptides in pathogen killing is under debate,
charge diﬀerences between cationic peptides and lipids on
the membrane are considered crucial. This may be the basis
for their selective activity as nonhemolytic peptides have a
high net positive charge distributed along the peptide length,
whereas hemolytic peptides have a low negative charge [10,
11]. Evidence suggests that AMPs have intracellular targets.
This is exempliﬁed by elaﬁn, a cationic and α-helical human
innate defense AMP that does not lyse the bacterial mem-
brane and is translocated into the cytoplasm. In vitro analysis
using a mobility shift assay revealed that elaﬁn binds DNA
[18]. The histone-derived peptide buforin II binds nucleic
acids in gel retardation assays and rapidly kills Escherichia
coli by translocating into the cytoplasm of the pathogen and
probably interfering with the functions of DNA or RNA.
The structurally similar magainin 2 also kills E. coli but does
not enter the cytoplasm [19]. Similarly, cationic antibacterial
peptides enter the cytoplasm of Aspergillus nidulans and
kill the fungus by targeting intracellular molecules whose
identity has not been veriﬁed [20]. An excellent review of
theintracellular targetsof AMPswasrecentlypublished [21].
More studies are required, however, to conﬁrm the existence
and actual mode of action of AMPs with intracellular targets.
Insects produce AMPs constitutively at local sites or the
AMPs are released systemically upon pathogenic infection to
initiate pathogen-killing activities. In addition to the well-
characterized Drosophila and mouse innate immune signal-
ing pathways, the sequencing of the Tribolium genome has
boosted research progress because bioinformatics analyses
revealed putative immune-related genes based on compar-
isons with the genomes of other species [22].
AMPs are multifunctional molecules that, in addition to
their well-known role as eﬀectors of the innate immune sys-
tem,areinvolvedinseveralbiologicprocessesandpathologic
conditions, such as immune modulation, angiogenesis, and
cytokine and histamine release [23–27]. Probably due to the
negative charge in the plasma membrane of many cancer
cells,somecationicpeptidesalsohaveanticanceractivity[28,
29]. These properties can be potentially exploited for clinical
purposes [12, 30]. Cecropins are selectively cytotoxic to
cancer cells, preventing their proliferation in bladder cancer,
and are therefore likely candidates in strategies for the devel-
opment of anticancer drugs [31]. In addition to antimicro-
bial activity, defensins facilitate the induction of adaptive
immunityandpromotecellproliferationandwoundhealing.
Defensins show chemotactic activity whereby dendritic cells,
monocytes, and T cells are recruited to the site of infection.
Moreover, human β-defensins and the cathelicidin LL-37
stimulate the production of pruritogenic cytokines, such as
interleukin-31, leukotrienes, prostaglandin E2, and others,
suggesting an important role in allergic reactions [32–34].
AMPs also form the basis of the potentially lucrative com-
mercial area of “cosmeceuticals”-products with beneﬁcial
topical activities that are delivered by rubbing, sprinkling,
spraying, and so forth [35].
Here, we review the progress made in discovery of co-
leopteran AMPs, the molecular basis of Tribolium innate
immunity, and prospects for the application of antimicrobial
peptides in medicine.
2. The DiscoveryProcess
2.1. Antimicrobial Peptides in Tribolium . The ﬁrst wide-scale
study of Tribolium immunity was conducted by Zou et al.
in 2007 [22]. Taking advantage of the fully sequenced Tri-
bolium genome to predict putative immune genes using bi-
oinformatics techniques and real-time polymerase chain
reaction (PCR), Zou et al. [22] predicted 12 AMPs in Tri-
bolium compared to 20 in Drosophila, the most studiedInternational Journal of Microbiology 3
invertebrate. Another study using suppression subtractive
hybridization led to the addition of a few more AMPs to this
list [36] (see Table 1). Both studies identiﬁed four defensins
in Tribolium, and phylogenetic analysis indicated that three
of these are found in the evolutionary branch comprising
only coleopterans. The fourth defensin (Def4) is found in
a mixed branch that includes hymenopterans. A search of
theDefensinsKnowledgebase[37]revealedthatthesequence
information of this defensin is not available in the public
domain, although its existence has been reported [22]. Atta-
cins, which were identiﬁed in lepidopterans, were found in a
clusterofthreegenes.Attacinsarerichinglycineandproline,
are structurally similar to coleoptericins, and are inducible
by bacteria. Furthermore, Drosophila studies demonstrated
that the induction of attacin is reduced in both imd and
Tl− mutants [38]. Coleoptericins were ﬁrst isolated from the
larvae of Allomyrina dichotoma beetles immunized with E.
coli. Coleoptericins also show activity against Staphylococcus
aureus, methicillin-resistant S. aureus,a n dBacillus subtilis.
Like attacins, but unlike cecropins, coleoptericins do not
form pores on the bacterial membrane, but do cause defects
in cell division, as liposomes containing E. coli or S. aureus
membrane constituents do not leak upon treatment with the
recombinant form of coleoptericin, but instead form chains
[39].
Tribolium cecropins are predicted to be pseudogenes be-
cause of a shift in the open reading frame; some cecropin-
related proteins with an unusual structure, however, have
been reported [22] .Ac e c r o p i nh a sb e e nr e p o r t e di na tl e a s t
one coleopteran, Acalolepta luxuriosa [44].
Fourthaumatin-likegeneswerefoundinTriboliumusing
suppression subtractive hybridization and genome search.
Experimentally, septic injury induces thaumatin-1 and
defensins in Tribolium [36]. Sterile wounding also induces
thaumatin-1 and defensin-2. Furthermore, recombinant
thaumatin-1 heterologously overexpressed in E. coli is active
against fungi [36]. Coleopteran cationic peptides might be
remarkably diﬀerent from other known peptides and are
thereforenotreadilyidentiﬁedbyhomologysearches.Aclear
homolog of the Drosophila antifungal drosomycin could not
be found in the Tribolium genome, but a weakly homologous
protein with a cysteine-rich sequence was detected [22].
An overview of Tribolium AMPs indicates similarities with
other coleopterans, but some diﬀerences with Drosophila.
The work reported by these groups provides a good basis for
advancing research on coleopteran AMPs.
2.2. Other Antimicrobial Peptides Identiﬁed in Coleopterans.
A number of AMPs present in certain coleopterans have not
yet been identiﬁed in Tribolium (see Table 2). One of these is
an interesting class of insect peptides that adopts the knottin
fold and was ﬁrst identiﬁed in 2003 from the harlequin bee-
tle, Acrocinus longimanus. Members of this class include Alo-
1, Alo-2, and Alo3 [42]. Psacotheasin from the yellow star
longhorn beetle Psacothea hilaris has also been identiﬁed as
a member of this class [43, 45]. Alo-3 is active against fungi,
while psacotheasin is active against bacteria and fungi. The
knottin fold is characterized by a disulﬁde topology of the
“abcabc”type,inwhichdisulﬁdebridgesareformedbetween
the ﬁrst cysteine and the fourth, second, and ﬁfth cysteines,
and the third and sixth cysteines [46]. Disulﬁde bridge for-
mation may confer important properties to the peptides,
suchasstabilityandresistancetoproteasecleavage.Members
of the knottin family in general have low sequence simi-
larity, reducing their chances of identiﬁcation by homology
searches [46]. In contrast, however, the coleopteran knottin
fold AMPs share sequence similarities with several plant
antifungal peptides [42]. Although the mechanism by which
these peptides function is not fully understood, psacotheasin
kills Candida albicans by inducing apoptosis [47]. This has
clinical signiﬁcance as C. albicans can cause mild superﬁcial
to severe infections in immunocompromised patients. A
better understanding of the molecular events that are critical
to the induction of apoptosis by cationic peptides could lead
to new targets for antifungal drug development. Alarmingly,
candidemia, a systemic Candida infection, is on the increase
and is accompanied by the reemergence of resistance against
common drugs, pointing to the urgency of ﬁnding alterna-
tive means of treating fungal infections [48, 49].
2.3. Databases. The Antimicrobial Peptides database, a com-
prehensiveandsearchabledatabaseforAMPswasestablished
based on information from literature surveys [50, 51]. Cur-
rently, an updated version on the website indicates that there
are1773cationicpeptidesinthedatabase,includingantiviral
(5.8%), antibacterial (78.56%), antifungal (31.19%), and
antitumor(6.14%)peptides.Someofthesepeptidesfunction
against more than one type of pathogens. The structures of
231 of these peptides have been determined by nuclear mag-
netic resonance and X-ray diﬀraction studies. Another useful
database is the Defensins Knowledgebase, which allows text-
based searches for information on this large family of AMPs
[37]. It is a manually curated and specialized database sim-
ilar to the shrimp penaeidin database, PenBase [52]. We have
also started molecular studies of another coleopteran, the
dung beetle Euoniticellus intermedius, and sequenced the
adult transcriptome with a view to study its immune system
[53]. These databases serve as useful tools for the discovery
and design of new peptides. Indeed, key features upon which
antimicrobial activity is based have been studied using the
Antimicrobial Peptides database [54, 55]. Such analyses gen-
erate an important information pool for drug design.
3. Regulation of AMP Expression
by Coleopterans
The signaling pathways that mediate the immune response
in Tribolium castaneum were initially predicted based on a
combination of in silico studies and experimental work by
Zou et al. [22] and more recently another study involving
the burying beetle Nicrophorus vespilloides [56]. In addition,
studies using adult beetles exposed to E. coli, M. luteus,
C. albicans, and S. cerevisiae have provided information on
the signaling pathways. Accordingly, large-scale studies using
real-time PCR revealed the presence of innate immune
genes, such as PGRP-LA, PGRP-LE, PGRP-SA, PGRP-SB,4 International Journal of Microbiology
Table 1: Antimicrobial peptides currently predicted or identiﬁed in Tribolium.
Antimicrobial peptide Accession number Reference Target Method of identiﬁcation
Attacin1 GLEAN 07737 [22] Homology searches
Attacin2 GLEAN 07738 [22] Homology searches
Attacin3 GLEAN 07739 [22] Homology searches
Cecropin1 GLEAN 00499 [22, 31] Antibacterial, antitumor Homology searches
Cecropin2 Cec2 [22, 31] Antibacterial, antitumor Homology searches
Cecropin3 GLEAN 00500 [22, 31] Antibacterial, antitumor Homology searches
Defensin1 GLEAN 06250;
XM 962101 [22, 36] Antibacterial Homology searches and suppression
subtractive hybridization
Defensin2 GLEAN 10517;
XM 963144 [22, 36] Antibacterial Homology searches and suppression
subtractive hybridization
Defensin3 GLEAN 12469;
XM 968482 [22, 36] Antibacterial Homology searches and suppression
subtractive hybridization
Defensin4 Def4 [22] Homology searches
Coleoptericin1 GLEAN 05093 [22] Antibacterial Homology searches
Coleoptericin2 GLEAN 05096 [22] Antibacterial Homology searches
Similar to thaumatin family XM 963631 [36] Antifungal Suppression subtractive hybridization
Probable antimicrobial peptide Tc11324 [22] Homology searches
Putative antimicrobial peptide AM712902 [36] Suppression subtractive hybridization
Table 2: Antimicrobial peptides expressed in other coleopterans not yet identiﬁed in Tribolium.
Antimicrobial peptide Organism Accession no. Reference
Diptericin A S. zeamis, (G. morsitans) Q8WTD5 [40]
Acaloleptin A S. zeamis (A. luxuriosa) Q76K70 [40]
Sarcotoxin II-1 S. zeamis, (S. peregrina) P24491 [40]
Tenecin-1 S. zeamis, (T. molitor) Q27023 [40, 41]
Tenecin-2 T. molitor [41]
Luxuriosin S. zeamis, (A. luxuriosa) Q60FC9 [40]
Alo-3 (knottin type) A. longimanus P83653 [42]
Psacotheasin (Knottin
type) P. hilaris [43]
several Toll proteins, and the immune deﬁciency (IMD) pro-
tein. Notably, some of the PGRPs had no orthologs in Dro-
sophila, indicating a diversity of speciﬁcity. Recent biochem-
ical studies using the large beetles Tenebrio molitor and Hol-
otrichia diomphalia further elucidated the extracellular sig-
naling network involved in responses to fungal and bacterial
infections [41, 57]. Overall, coleopteran signaling appears to
occur via the Toll and IMD pathways (Figure 1).
The Toll pathway is activated by PAMPS such as β-1,3-
glucans, found in fungi, and by Lys-type peptidoglycans
(PGN), found primarily in Gram-positive bacteria. A com-
plex of the PAMPS and pathogen recognition receptors
(PRRs) activates an apical protease, leading to a three-step
serine protease cascade that culminates in the generation of
active spa¨ etzle, the ligand of the transmembrane receptor
Toll.Subsequentintracellularsignalingleadstothetranscrip-
tional activation of genesthatencode antimicrobial peptides.
Activation of the immune response by DAP-type PGN
found primarily in Gram-negative bacteria and Gram-
positive bacilli is still poorly understood in ﬂies and beetles.
Generally, it is understood that Gram-negative bacteria
require the IMD pathway because imd− mutants cannot ex-
press antimicrobial peptides against Gram-negative bacte-
ria. In Drosophila, candidates for the signal transduction-
activated Gram-negative bacteria are the transmembrane
receptor PGRP-LC and PGRPP-LE. Both molecules can
activate the IMD pathway [3, 58]. Because these molecules
are present in beetles and PGRP-LE is orthologous to the
Drosophila protein, it is likely that the corresponding path-
ways are conserved. In Tribolium, PGRP-LA and PGRP-LE
are activated by bacterial infection, but poorly activated by
C. albicans and M. luteus [22]. Other Tribolium studies show
that the IMD pathway is activated by two Gram-negative
bacteria, Xenorhabdus nematophila and E. coli, inducing 12
AMPs of which 5 are signiﬁcantly dependent on the IMD
pathway as demonstrated by RNA interference studies [59].
The same study, however, demonstrated that two Gram-
positive bacteria with diﬀerent peptidoglycans expressed the
same AMPs with only defensin-1 being dependent on Toll.
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Figure 1: Activation mechanisms in the coleopteran immune system. Immune response pathways activated by bacteria and fungi showing a
pathogen-associated recognition pattern (PAMP), pattern recognition receptors (PRRs), and downstream signaling molecules. The protease
cascade in the Toll pathway involves the modular apical modular serine protease (MSP), the Spz-processing enzyme-activating enzyme
(SAE), and the spa¨ etzle processing enzyme (SPE). GNBP3: glucan binding protein 3; PGRP: peptidoglycan recognition protein.
maybeconserved,diﬀerencesinPAMPSrecognitionandsig-
nal transduction exist between Tribolium and Drosophila.
The discovery of another PRR known as the LPS recog-
nition protein (LRP) based on its E. coli agglutinating prop-
erties suggests the existence of an LPS pathway. LRP circu-
lates in the hemolymph and does not agglutinate S. aureus
or C. albicans. Interestingly, LRP comprises six repeats of an
epidermal-growth-factor- (EGF)-like domain, an unusual
structural feature for PRRs [60]. The downstream events in
this pathway remain unclear.
4.AntimicrobialPeptidesinClinicalMedicine
Cationic peptides have emerged as important targets for the
development of therapeutics against bacteria, fungi, viruses,
and parasites. They are key eﬀector molecules in host de-
fense through direct and indirect antimicrobial activity. Fur-
thermore, in vertebrates, these peptides mediate a variety of
cellular processes such as immunomodulation, wound heal-
ing, and tumorigenesis. These roles provide opportunities
for the development of therapeutic products and vaccines.
AMPsareattractivemoleculesforthedevelopmentofclinical
and veterinary therapeutics because they are fast acting and
eﬀective against susceptible pathogens, are less likely to cause
the emergence of resistance compared to traditional antibi-
otics, have low toxicity to mammalian cells, and their mode
of action tends to be more physical rather than targeted at
metabolic pathways. A search of the FreePatentsOnline data-
base using the word “antimicrobial peptide” produced more
than 66.000 hits, and a number of AMPs have undergone
clinical development [30]. A recent review of cationic pep-
tides lists the peptides that are in various stages of clinical
trials [29].
As mentioned above, the predicted Tribolium AMPs
include defensins, attacin, coleoptericin, thaumatin, and ce-
cropin. Defensins exhibit a broad spectrum of antimicrobial
activity directed at bacteria, fungi, and viruses and are prob-
ably the most studied class of AMPs. Many therapeutic pro-
ducts have been modeled on them. The diﬀerent types of
defensins are either expressed constitutively or induced by
infections to control the composition of microorganisms on
surfaces such as the small and large intestines [61].6 International Journal of Microbiology
Many challenges remain that hamper the development
of commercially viable peptides. The pressing issues concern
pharmacokinetics (how the body deals with peptide drugs).
When peptides are administered orally, the gastrointestinal
tract may prevent their reabsorption into the systemic cir-
culation. Furthermore, peptides may elicit an antigenic re-
sponse when injected directly in the blood. This leaves
topical medication the most feasible formulation while more
research is being pursued to address the remaining obstacles.
Despite these obstacles, the prospects for AMPs are not bleak
because some have proceeded to clinical application. There
is some optimism that these obstacles may soon be overcome
by new strategies that combine natural cationic peptides and
stable synthetic immunomodulatory peptides [29]. In this
regard, peptide drugs such as Polymyxin B and gramicidin
that are used for the treatment of Gram-negative bacterial
infections are reported to be safe and eﬀective, and peptides
such as the indolicidin-derived CLS001 (previously known
as MX594AN) have reached phase III clinical trials with
promising prospects [62–64]. Because of their evolutionary
distance, during which their survival against microbes has
been solely dependent on innate immunity, insects provide
interesting models for novel AMP drug design [65, 66].
5. Conclusions
The emergence of multidrug-resistant pathogens threatens
human health globally and presents an urgent need to ﬁnd
antimicrobials with a reduced chance of inducing resistance.
Cationic peptides for which the mechanism of action
involves targeting the plasma membrane in a nonspeciﬁc
manner, but does not involve speciﬁc proteins, oﬀer good
prospects. Admittedly, more work is needed to elucidate the
mechanism of action of these peptides, as there is some
evidence for intracellular targets. The importance of cationic
peptidesisfurtherhighlightedbytheiremergingprospectsin
other aspects of medicine, such as cancer treatment and vac-
cine development. Coleopterans are the most evolutionarily
successful group of insects and are more representative of
insects than Drosophila. In addition, human genes are more
comparable to those of Tribolium than those of Drosophila.
Thus, coleopterans are emerging as an important species
for study as, like vertebrates, they have retained ancestral
genes that are not present in Drosophila. Indeed, there is
overwhelming evidence that coleopterans are more suitable
for comparative studies between phyla than the commonly
used dipterans. Here, we suggest that perhaps the outstand-
ing evolutionary success of coleopterans is consistent with a
robust immune system that warrants more attention than it
has received to date.
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